pharmaceuticals and pharmaceutical research and development . founded march 1984 ; 32 years ago 1984 03 in libertyville illinois united states founder allen chao ph.d. and david hsia ph.d. headquarters dublin ireland and parsippany troy hills new jersey united states . number of locations 40 manufacturing facilities 27 global r & d centers and marketing sales facilities worldwide . area served 100 countries key people paul bisaro executive chairman brenton l. saunders president and ceo products branded and generic pharmaceuticals revenue us 13.062 billion 2014 operating income us 1.090 billion 2014 net income us 1.630 billion 2014 total assets us 6.881 billion 2014 total equity us 28.335 billion 2014 number of employees 21 600 feb. 2015 parent teva pharmaceuticals website www.actavis.com actavis generics 1 formerly known as watson pharmaceuticals and actavis plc prior to the acquisition of allergan inc is a global pharmaceutical company focused on developing manufacturing and commercializing branded pharmaceuticals generic and over the counter medicines and biologic products . actavis has a commercial presence across approximately 100 countries . the company has global headquarters in dublin ireland and administrative headquarters in parsippany troy hills new jersey united states . 2 actavis plc markets brand products through six franchises in key therapeutic categories including aesthetics dermatology plastic surgery ; neurosciences cns ; eye care ; women s health and urology ; gi and cystic fibrosis ; and cardiovascular disease and infectious disease . 3 the company s products include botox 4 namenda restasis 5 linzess bystolic 6 juvederm 7 latisse 8 lo loestrin fe estrace teflaro dalvance ozurdex 9 optive 10 natrelle 11 viibryd liletta saphris 12 enablex actonel androderm gelnique and others . actavis plc also operates the world s third largest generics business . the company is ranked in the top 3 in 12 global markets the top 5 in 16 global markets and in the top 10 in 33 global markets . actavis also develops and out licenses generic pharmaceutical products outside the u.s. through its medis third party business the world s largest generic pharmaceutical out licensing business . medis has more than 300 customers globally and offers more than 200 products . 13 actavis plc is also developing biosimilars products in oncology and other therapeutic categories and currently has five biosimilar products in development . 14 actavis plc has more than 40 manufacturing and distribution facilities around the world with a capacity of approximately 40 billion units annually . actavis global operations also includes anda inc. the fourth largest u.s. generic pharmaceutical product distributor in the united states . 15 on june 15 2015 actavis plc changed its name to allergan plc but the company s u.s. and canadian generics business will continue to operate under the actavis name . 16 in july 2015 allergan plc announced it would sell its generics division of the company to teva pharmaceuticals for 40.5 billion 17 18 a transaction proposed for completion by the first quarter of 2016 . 19 contents 1 history 2 company evolution 2.1 the 1990s 2.2 2000 to 2009 2.3 2011 to 2014 2.3.1 actavis acquisition and watson name change 2.3.2 warner chilcott plc acquisition 2.3.3 forest laboratories acquisition 2.3.4 allergan inc acquisition and actavis plc name change 3 locations and facilities 3.1 global headquarters 3.2 manufacturing facilities 3.3 research and development facilities 4 references 5 external links history edit the company was founded in the spring of 1983 20 when with funding from friends and family colleagues allen chao ph.d. and david hsia ph.d. began a small drug development enterprise . just two months later the founders established an initial product development and analytical laboratory with six employees including both founders in a leased space in libertyville illinois . by late fall of the same year the company moved to southern california into an initial 2 000 square foot 190 m2 leased facility in corona and the development and manufacturing of generic pharmaceuticals began . 21 the corona site became the corporate headquarters for the rapidly expanding u.s. company . company evolution edit the 1990s edit throughout its history actavis has expanded both organically and as the result of strategic acquisitions . in 1993 actavis then watson announced its initial public offering ipo of shares of common stock . the company was initially listed on the nasdaq under the ticker symbol wats . the company moved to the new york stock exchange nyse in 1997 and began trading under the symbol wpi . actavis facility in iceland 2000 to 2009 edit in 2000 the company acquired schein pharmaceutical inc. an acquisition that more than doubled the company s size . 22 in that same year the group reported revenues in excess of 1 billion . in the fall of 2006 it acquired andrx corporation a fort lauderdale fl based pharmaceutical company making it the third largest specialty pharmaceutical company based on total prescriptions dispensed . 23 in 2007 dr. allen chao retired as president and chief executive officer ceo and was succeeded by paul m. bisaro . 24 the company s international presence began with the acquisition of the arrow group in 2009 providing the company with commercial presence in more than 20 international markets . 25 as a result of the arrow acquisition the company also acquired the biopharmaceutical development organization eden biodesign in liverpool uk . 26 2011 to 2014 edit in 2011 the company moved its corporate headquarters from corona california to parsippany new jersey . the new leed certified corporate headquarters at the morris corporate center in parsippany was formally dedicated on june 9 2011 . 27 actavis acquisition and watson name change edit in november 2012 watson acquired the switzerland based global generics company actavis group for eur4 .25 billion creating the world s third largest generics company with a leading position in key established commercial markets including the u.s. uk nordics canada australia and emerging markets in central and eastern europe and russia . 28 following the acquisition watson adopted actavis name for its global operations . warner chilcott plc acquisition edit on october 1 2013 actavis acquired irish pharmaceutical company warner chilcott plc previously known as galen in a stock for stock transaction valued at approximately 8.5 billion . 29 the combination created a company with approximately 10 billion in anticipated combined annual 2013 revenue and the third largest u.s. specialty pharmaceutical company with approximately 3 billion in annual revenue focused on the core therapeutic categories of women s health urology gastroenterology and dermatology . in association with the merger the company relocated its corporate headquarters to ireland while maintaining its operational headquarters in parsippany taking advantage of the lower 17 % vs. 35 % in the united states irish corporate tax rate . 30 this deal inspired a series of similar moves by other drug companies and led to new treasury department regulations limiting the ability of companies to perform such inversions although actavis was exempt from these regulations as its move abroad had already been completed . 31 ceo paul bisaro stated that in making the inversion they were trying to level the playing field given the high corporate tax rate in the united states . 32 forest laboratories acquisition edit on july 1 2014 actavis announced that it had completed its acquisition of forest laboratories who previously acquired furiex pharmaceuticals inc and aptalis pharma in a cash and equity transaction valued at approximately 25 billion . 33 following the acquisition the company restructured its executive leadership with paul bisaro being named executive chairman and brent saunders being appointed ceo and president of the combined organization . 34 allergan inc acquisition and actavis plc name change edit in november 2014 actavis plc announced its intention to acquire allergan inc the manufacturer of botox 35 completion of the deal would increase its market capitalization to 147 billion . 36 37 on march 17 2015 actavis plc completed the acquisition of allergan inc in a cash and equity transaction valued at approximately 70.5 billion . the combination created a 23 billion diversified global pharmaceutical company with commercial reach across 100 countries . in june 2015 actavis plc officially changed its name to allergan plc. 38 allergan plc formerly known as actavis until june 2015 when it adopted allergans name actavis plc auden mckenzie holdings limited acq 2015 by actavis durata therapeutics acq 2014 by actavis forest laboratories acq 2014 by actavis furiex pharmaceuticals inc acq 2014 by forest aptalis pharma eurand pharmaceuticals & axcan pharma merged 2011 acq 2014 by forest galen acq 2013 by actavis warner chilcott plc acq 2000 by galen adopted warners name procter & gamble s prescription drug unit acq 2009 by warner watson pharmaceuticals andrx corporation acq 2006 by watson arrow group acq 2009 by watson eden biodesign acq by watson specifar pharmaceuticals s.a. acq 2011 by watson ascent pharmahealth ltd acq 2012 by watson actavis group acq 2012 by watson adopted actavis name allergan inc kythera biopharmaceuticals acq 2015 map pharmaceuticals inc acq 2013 inamed corporation acq 2006 allergan advanced medical optics spun off in 2006 locations and facilities edit global headquarters edit the company s global headquarters are located in dublin ireland and administrative headquarters are located in parsippany new jersey usa . 39 manufacturing facilities edit the company has 40 manufacturing facilities in five continents providing the company with a core leadership position in modified release products solid oral dosages transdermals semi solids liquids and injectables . the company s manufacturing facilities are located in belgium brazil bulgaria canada china france germany greece iceland india indonesia ireland northern ireland italy malta puerto rico romania singapore serbia thailand uk and usa . research and development facilities edit actavis plc has 27 global r & d facilities focusing on the development of modified release products solid oral dosages transdermals semi solids liquids and injectables around the world . the company s r & d facilities are located in belgium bulgaria china france iceland italy india indonesia ireland japan northern ireland romania uk and usa . references edit http www.fiercepharma.com pharma analyst cuts allergan generics sales estimates as teva deal close nears actavis plc . marketwatch . form 10k . actavis plc. botox cosmetics . allergan . restasis pdf . allergan . bystolic . actavis . juvederm . allergan . latisse pdf . allergan . ozurdex . allergan . optive . allergan . natrelle . allergan . form 10k . actavis plc. actavis confirms favorable ruling in generic pulmicort respules patent suit . first word pharma . john carroll . can actavis deliver a promised 6b boost from this pipeline . fierce biotech . actavis confirms favorable ruling in generic pulmicort respules patent suit . first word pharma . haggerty neil 2015 06 15 . actavis changes name to allergan after deal for botox maker . wsj . retrieved 2015 08 07 . allergan accelerates transformation to branded growth pharma leader by divesting global generics business to teva for 40.5 billion press release . allergan . 27 july 2015 . retrieved 4 december 2015 . yoel minkoff 27 july 2015 . teva to buy allergan generics for 40.5 b . seeking alpha . retrieved 4 december 2015 . o donnell carl 3 december 2015 . teva divesting 1 billion in assets to clear allergan deal . reuters . retrieved 4 december 2015 via yahoo finance . act profile actavis plc ordinary shares stock yahoo finance . yahoo.com . watson pharmaceuticals acquired arrow group for 1.75 b . tbi . watson pharmaceuticals agrees to buy a rival . ny times . 2000 05 26 . watson pharmaceuticals to buy andrx corp . pharmacytimes.com . watson pharmaceuticals inc. says ceo to retire names replacement . fierce biotech . shannon pettypiece 2009 06 17 . watson agrees to buy arrow group for 1.75 billion . bloomberg . dead link gareth macdonald . watson buys eden biodesign . biopharma reporter.com . generic drug maker watson opening research operations in north brunswick . nj.com . eyk henning 2012 04 25 . watson actavis to